How Far We Have Come and Where We Need to Go is a Canadian white paper exploring the use of long-acting injectable antipsychotics (LAIs) in schizophrenia and related psychotic disorders. Developed through a multidisciplinary workshop led by EPI Canada, the report examines the benefits of LAIs in improving treatment adherence, reducing relapse and hospitalization rates, and supporting long-term recovery. The paper also highlights ongoing barriers to wider LAI use in Canada, including stigma, education gaps, transitions of care, and access challenges, and outlines practical strategies to improve awareness, clinician education, and patient-centred care. ​